NRXP NRx Pharmaceuticals, Inc.
Price Chart
Executive Summary
NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes to support the company's clinical-stage pipeline for CNS disorders.
Key Financial Metrics
Actionable Insight
The dilutive offering at a 2.8% discount to the current price (assuming $3.60 close) adds overhang. Monitor for further dilution if the shelf is tapped again. The company's cash runway extends but at the cost of shareholder value.
Key Facts
- Closed underwritten public offering of common stock at $3.50 per share
- Gross proceeds of approximately $22.3 million
- Proceeds to be used for working capital and general corporate purposes
- BTIG and Lucid Capital Markets acted as bookrunners
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
Dilution of approximately 6.37 million shares at $3.50 per share, representing about 15% of pre-offering shares outstanding (based on $147M market cap / $3.50 = 42M shares pre-offering). Gross proceeds of $22.3 million.
Risk Factors
- Further dilution from remaining shelf capacity
- Clinical-stage pipeline with no approved products; regulatory and commercial risks
- Potential for additional capital raises given operating losses
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307137 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
11d ago
|
Press Release
| $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $3.97 (−4.11%) |
|
Jun 4, 2026
12d ago
|
Press Release
| $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $3.97 (+4.11%) |
|
Jun 3, 2026
13d ago
|
Press Release
| $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $3.97 (+1.98%) |
|
Jun 2, 2026
14d ago
|
Press Release
| $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $3.97 (+1.98%) |
|
May 18, 2026
29d ago
|
Press Release
| $3.12 $4.31 | ▲ +38.36% | ▲ +36.74% | $3.97 (+27.45%) |
|
May 14, 2026
4w ago
|
Press Release
| $3.21 $3.06 | ▼ −4.67% | ▼ −3.96% | $3.97 (+23.68%) |
|
Mar 30, 2026
11w ago
|
Press Release
| $2.09 $2.23 | ▲ +6.70% | ▲ +2.40% | $3.97 (+89.95%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $1.84 $2.38 | ▲ +29.35% | ▲ +31.56% | $3.97 (+115.76%) |
|
Feb 24, 2026
16w ago
|
DEFA14A
| $1.91 $1.87 | ▼ −2.09% | ▼ −0.99% | $3.97 (+107.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access